This site is intended for UK healthcare professionals
Blocking progesterone may prevent or halt the development of breast and ovarian cancers in women with mutations of the BRCA1 gene, findings of a study suggest.
The study of mice lacking BRCA1 and the gene p53 showed that mammary tumours developed in an average of eight months. However, mice given the progesterone antagonist mifepristone were free of tumours at 12 months.
In mice lacking BRCA1 and p53, there were more epithelial cells with progesterone receptors than in mice lacking the gene p53 only.
The role of progesterone in BRCA1-mutation cancers could explain why they occur only in breast and ovarian tissue.
The voice for today's GP. News, insights and clinical education.
Cases of TB in England have risen by 7% compared with last year, prompting a warning...
GP leaders in England have demanded an investigation into 'mismanagement' of this...
GP leaders have raised concerns over the 'engineering' of general practice after...
Specialist, associate specialist and specialty (SAS) doctors in England could join...
Doctors' leaders will oppose government plans to expand use of physician associates...
The general public believe the government should reopen talks to end doctor strikes...
